Aleteia logoAleteia logoAleteia
Thursday 07 December |
Saint of the Day: St. Ambrose of Milan
Aleteia logo
separateurCreated with Sketch.

Promising study shows Stevia could cure Lyme disease



Zelda Caldwell - published on 03/16/17

Preliminary studies show that the plant-based sweetener is more effective than antibiotics

Lyme disease is notoriously difficult to cure. Conventional antibiotics, while effective in most patients, leave 10 to 20 percent of patients with lingering symptoms, broadly characterized as “chronic Lyme disease.”

Now researchers have found promising evidence that the leaf extract Stevia, commonly used as a sweetener, may be an effective antidote to the B. burgdorferi bacteria that causes Lyme. A pre-clinical study published by the European Journal of Microbiology & Immunologyfound that the Stevia plant is able to harness its phytochemical defense system to protect against infection by the bacteria.

What’s more, as an article in GreenMedInfo notes, tests on the most antibiotic-resistant form of B. burgdorferi showed that the bacteria actually increased in mass when antibiotics were administered, while it decreased by about 40 percent after a dose of the Stevia extract.

Lyme disease sufferers should note that this research is only preliminary, and they shouldn’t necessarily stock up on Coca Cola Lite. Turns out that the stevoside extract used in the soft drink was not as effective in tests as “the real thing.”

Support Aleteia!

Enjoying your time on Aleteia?

Articles like these are sponsored free for every Catholic through the support of generous readers just like you.

Thanks to their partnership in our mission, we reach more than 20 million unique users per month!

Help us continue to bring the Gospel to people everywhere through uplifting and transformative Catholic news, stories, spirituality, and more.

Support Aleteia with a gift today!

Daily prayer
And today we celebrate...

Entrust your prayer intentions to our network of monasteries

Top 10
See More
Get Aleteia delivered to your inbox. Subscribe here.